Gerber Kawasaki Wealth & Investment Management Cuts Stock Position in Novo Nordisk A/S (NYSE:NVO)

Gerber Kawasaki Wealth & Investment Management trimmed its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 20.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 83,311 shares of the company's stock after selling 20,773 shares during the quarter. Gerber Kawasaki Wealth & Investment Management's holdings in Novo Nordisk A/S were worth $7,166,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Three Seasons Wealth LLC bought a new position in Novo Nordisk A/S in the fourth quarter worth approximately $325,000. Empire Financial Management Company LLC boosted its position in Novo Nordisk A/S by 26.4% during the 4th quarter. Empire Financial Management Company LLC now owns 2,439 shares of the company's stock valued at $210,000 after acquiring an additional 509 shares in the last quarter. Banco Bilbao Vizcaya Argentaria S.A. boosted its position in Novo Nordisk A/S by 2,249.3% during the 4th quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 99,470 shares of the company's stock valued at $8,550,000 after acquiring an additional 95,236 shares in the last quarter. Coppell Advisory Solutions LLC boosted its position in Novo Nordisk A/S by 31.6% during the 4th quarter. Coppell Advisory Solutions LLC now owns 28,048 shares of the company's stock valued at $2,405,000 after acquiring an additional 6,732 shares in the last quarter. Finally, Oxford Wealth Group LLC boosted its position in Novo Nordisk A/S by 20.1% during the 4th quarter. Oxford Wealth Group LLC now owns 14,989 shares of the company's stock valued at $1,289,000 after acquiring an additional 2,506 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Sanford C. Bernstein raised Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. Dbs Bank cut Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. BMO Capital Markets reissued a "market perform" rating and issued a $64.00 price objective (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Stifel Nicolaus lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Finally, StockNews.com upgraded shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a report on Friday, April 25th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $135.00.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock traded up $0.81 during mid-day trading on Wednesday, hitting $65.97. The company had a trading volume of 6,334,272 shares, compared to its average volume of 6,146,788. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 12-month low of $57.00 and a 12-month high of $148.15. The company's fifty day moving average is $72.84 and its 200-day moving average is $88.85. The company has a market capitalization of $296.04 billion, a price-to-earnings ratio of 20.05, a P/E/G ratio of 0.90 and a beta of 0.61.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Tuesday, April 8th. Investors of record on Monday, March 31st were issued a $0.7874 dividend. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.51. This represents a yield of 1.2%. The ex-dividend date was Monday, March 31st. Novo Nordisk A/S's payout ratio is 49.54%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.